Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
I was joking in the beginning part there. But if you knew what they were why didn’t you say what they were? Now if you excuse me I need to order some tapeworms off of the dark web.